Concepedia

F. Stelma

FS

Statistics

Publications

15

Citations

719

H-Index

13

Active since

2014

Affiliations

Amsterdam UMC Location University of Amsterdam(Current)

University Medical Center Groningen

Sanquin

University of Amsterdam

Regulus Therapeutics (United States)

F. Stelma is an author at Amsterdam UMC Location University of Amsterdam specializing in medicine, hepatology, and hepatitis.

Top concepts

Publications per year

2014–2022

15

Publications

15

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

Meike H. van der Ree, J. Marleen de Vree, F. Stelma et al. · The Lancet · 2017 · 259 citations

, , +7

Human intrahepatic CD69 + CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity

F. Stelma, A. de Niet, Marjan J. Sinnige et al. · Scientific Reports · 2017 · 104 citations · Full text

Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir

F. Stelma, A. de Niet, Marjan J. Tempelmans Plat-Sinnige et al. · The Journal of Infectious Diseases · 2015 · 53 citations · Full text

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101

F. Stelma, Meike H. van der Ree, Marjan J. Sinnige et al. · Hepatology · 2017 · 52 citations · Full text

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial

A. de Niet, Louis Jansen, F. Stelma et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 49 citations

, , +9

1–5 of 15